EMA adopts positive opinion for Merck’s KEYTRUDA® (pembrolizumab) as adjuvant therapy
Merck announced that the CHMP of the EMA has adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in treatment of patients with melanoma with lymph node involvement who have undergone complete surgical resection. October 22, 2018